Notably, the recent ALINA trial revealed that adjuvant alectinib, a second-generation ALK-TKI, significantly enhanced disease-free survival compared to platinum-based chemotherapy among patients with resected ALK-positive NSCLC of stage IB, II, or IIIA (18). This evidence concerns the gene ALK and non-small cell lung carcinoma.